Jiangsu Aidea Pharmaceutical Group (688488.SH): First Patient Successfully Enrolled in Phase III Clinical Trial for ACC017 Tablets

Stock News11-07

Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) announced that its self-developed Class 1 new drug, ACC017 tablets, for the treatment of HIV, has commenced a multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablet-controlled Phase III clinical trial. The study aims to evaluate the efficacy and safety of ACC017 in treatment-naive adults infected with human immunodeficiency virus type 1 (HIV-1). The first patient was successfully enrolled on November 7, 2025.

ACC017 is a novel chemical-structured HIV integrase strand transfer inhibitor (INSTI) independently developed by the company. As a Class 1 new chemical entity, it effectively blocks the integration of the HIV genome into host DNA by inhibiting HIV integrase activity. The drug is intended for clinical use in treating HIV infections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108431155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108431155","market":"us","top_or_hot":-1,"title":"Jiangsu Aidea Pharmaceutical Group (688488.SH): First Patient Successfully Enrolled in Phase III Clinical Trial for ACC017 Tablets","media":"Stock News","content":"<p>Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) announced that its self-developed Class 1 new drug, ACC017 tablets, for the treatment of HIV, has commenced a multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablet-controlled Phase III clinical trial. The study aims to evaluate the efficacy and safety of ACC017 in treatment-naive adults infected with human immunodeficiency virus type 1 (HIV-1). The first patient was successfully enrolled on November 7, 2025.</p>\n<p>ACC017 is a novel chemical-structured HIV integrase strand transfer inhibitor (INSTI) independently developed by the company. As a Class 1 new chemical entity, it effectively blocks the integration of the HIV genome into host DNA by inhibiting HIV integrase activity. The drug is intended for clinical use in treating HIV infections.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangsu Aidea Pharmaceutical Group (688488.SH): First Patient Successfully Enrolled in Phase III Clinical Trial for ACC017 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangsu Aidea Pharmaceutical Group (688488.SH): First Patient Successfully Enrolled in Phase III Clinical Trial for ACC017 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 16:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) announced that its self-developed Class 1 new drug, ACC017 tablets, for the treatment of HIV, has commenced a multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablet-controlled Phase III clinical trial. The study aims to evaluate the efficacy and safety of ACC017 in treatment-naive adults infected with human immunodeficiency virus type 1 (HIV-1). The first patient was successfully enrolled on November 7, 2025.</p>\n<p>ACC017 is a novel chemical-structured HIV integrase strand transfer inhibitor (INSTI) independently developed by the company. As a Class 1 new chemical entity, it effectively blocks the integration of the HIV genome into host DNA by inhibiting HIV integrase activity. The drug is intended for clinical use in treating HIV infections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688488","symbol_name":"艾迪药业","start_time":0,"source_url":"","article_id":"1108431155","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108431155","pubTimestamp":1762505893,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) announced that its self-developed Class 1 new drug, ACC017 tablets, for the treatment of HIV, has commenced a multicenter, randomized,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688488":"艾迪药业","III":"信息服务","BK4134":"信息科技咨询与其它服务","BK0262":"其他制造"},"translate_title":"江苏爱德药业集团（688488.SH）：ACC017片III期临床首例患者成功入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688488":1,"III":1},"content_text":"Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) announced that its self-developed Class 1 new drug, ACC017 tablets, for the treatment of HIV, has commenced a multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablet-controlled Phase III clinical trial. The study aims to evaluate the efficacy and safety of ACC017 in treatment-naive adults infected with human immunodeficiency virus type 1 (HIV-1). The first patient was successfully enrolled on November 7, 2025.\nACC017 is a novel chemical-structured HIV integrase strand transfer inhibitor (INSTI) independently developed by the company. As a Class 1 new chemical entity, it effectively blocks the integration of the HIV genome into host DNA by inhibiting HIV integrase activity. The drug is intended for clinical use in treating HIV infections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108431155","isCrawlerRequest":true}